Cited by 270Lipoproteins and Cardiovascular HealthHealth Promotion and Cardiovascular PreventionDiabetes, Cardiovascular Risks, and Lipoproteins

The DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.

Results of the National Cholesterol Education (NCEP) Program Evaluation Project Utilizing Novel E-Technology (NEPTUNE) II Survey and Implications for Treatment Under the Recent NCEP Writing Group Recommendations

Davidson, Michael H., Maki, Kevin C., Pearson, Thomas A., Pasternak, Richard C., Deedwania, Prakash C., McKenney, James M., Fonarow, Gregg C., Maron, David J., Ansell, Benjamin J., Clark, Luther T., Ballantyne, Christie M.·2005·The American Journal of Cardiology

DOI 10.1016/j.amjcard.2005.04.019

Open this paper in CoChat — free account

Abstract

The most recent national survey of compliance with the National Cholesterol Education Program (NCEP) Adult Treatment Panel (ATP) guidelines was completed before ATP III and showed significant underachievement of low-density lipoprotein (LDL) cholesterol goals. The NCEP Evaluation ProjecT Utilizing Novel E-Technology (NEPTUNE) II was a national survey conducted in 2003. Of the 4,885 patients, 67% achieved their LDL cholesterol treatment goal, including 89%, 76%, and 57%, respectively, in the 0 or 1 risk factor, > or = 2 risk factors or coronary heart disease (CHD), and CHD risk equivalent categories. The percentage with triglyceride concentrations > or = 200 mg/dl (2.25 mmol/L) in each risk category who achieved their LDL cholesterol and non-high-density lipoprotein cholesterol goals was 64%, 52%, and 27%, respectively. Patients with diabetes (55%) and other CHD risk equivalents (40%) were less likely to have achieved their LDL cholesterol targets than those with CHD (62%). Of the 1,447 patients with cardiovascular disease, 75% could be classified as very high risk according to the new July 2004 NCEP Writing Group recommendations, and 17.8% of those at very high risk had an LDL cholesterol level of <70 mg/dl (<1.81 mmol/L). In conclusion, these results suggest improved lipid management compared with previous surveys. The largest treatment gaps were found for features new to ATP III as of July 2004, including goal achievement for patients with CHD risk equivalents and for non-high-density lipoprotein cholesterol targets. Most of those (75%) with cardiovascular disease in NEPTUNE II would be considered very high risk and candidates for aggressive therapy to reach the new optional treatment goals.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1016/j.amjcard.2005.04.019

Cites

6 of 6 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Summary of the second report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel II)
Grundy, S. M., Bilheimer, D. W., Chait, A., Clark, L. T., Denke, M. A., Havel, R. J., Hazzard, W. R., Hulley, S. B., Hunninghake, D. B., Kreisberg, R. A., et al. (1993) · JAMA · doi:10.1001/jama.269.23.3015 · Cited by 27,944
Self-citation
Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III)
Expert Panel on Detection, E. (2001) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.285.19.2486 · Cited by 26,011
Implications of Recent Clinical Trials for the National Cholesterol Education Program Adult Treatment Panel III Guidelines
Grundy, S. M., Cleeman, J. I., Merz, C. N. B., Brewer, H. B., Clark, L. T., Hunninghake, D. B., Pasternak, R. C., Smith, S. C., & Stone, N. J. (2004) · Circulation · doi:10.1161/01.cir.0000133317.49796.0e · Cited by 6,902
Self-citation
The Lipid Treatment Assessment Project (L-TAP)
Pearson, T. A., Laurora, I., Chu, H., & Kafonek, S. D. (2000) · Archives of Internal Medicine · doi:10.1001/archinte.160.4.459 · Cited by 1,012
Self-citation
Serum Total Cholesterol Concentrations and Awareness, Treatment, and Control of Hypercholesterolemia Among US Adults
Ford, E. S., Mokdad, A. H., Giles, W. H., & Mensah, G. A. (2003) · Circulation · doi:10.1161/01.cir.0000066320.27195.b4 · Cited by 355
Intensive Statin Therapy — A Sea Change in Cardiovascular Prevention
Topol, E. J. (2004) · New England Journal of Medicine · doi:10.1056/nejme048061 · Cited by 196

Show all 6 references

Sorted by citations

Triglycerides and Cardiovascular Disease: A Scientific Statement From the American Heart Association
Miller, M., Stone, N. J., Ballantyne, C., Bittner, V., Criqui, M. H., Ginsberg, H. N., Goldberg, A. C., Howard, W. J., Jacobson, M. S., Kris-Etherton, P. M., et al. (2011) · Circulation · doi:10.1161/cir.0b013e3182160726 · Cited by 1,871
Self-citation
Hyperlipidemia as a Risk Factor for Cardiovascular Disease
Nelson, R. H. (2012) · Primary Care Clinics in Office Practice · doi:10.1016/j.pop.2012.11.003 · Cited by 1,142
Dyslipidemia in type 2 diabetes mellitus
Mooradian, A. D. (2009) · Nature Reviews Endocrinology · doi:10.1038/ncpendmet1066 · Cited by 1,053
Inclisiran for the Treatment of Heterozygous Familial Hypercholesterolemia
Raal, F. J., Kallend, D., Ray, K. K., Turner, T., Koenig, W., Wright, R. S., Wijngaard, P. L. J., Curcio, D., Jaros, M. J., Leiter, L. A., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa1913805 · Cited by 818
Very Low Levels of Atherogenic Lipoproteins and the Risk for Cardiovascular Events
Boekholdt, S. M., Hovingh, G. K., Mora, S., Arsenault, B. J., Amarenco, P., Pedersen, T. R., LaRosa, J. C., Waters, D. D., DeMicco, D. A., Simes, R. J., et al. (2014) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2014.02.615 · Cited by 581
Effect of an RNA interference drug on the synthesis of proprotein convertase subtilisin/kexin type 9 (PCSK9) and the concentration of serum LDL cholesterol in healthy volunteers: a randomised, single-blind, placebo-controlled, phase 1 trial
Fitzgerald, K. J., Frank-Kamenetsky, M. D., Shulga‐Morskaya, S., Liebow, A., Bettencourt, B. R., Sutherland, J. E., Hutabarat, R. M., Clausen, V. A., Karsten, V., Cehelsky, J. E., et al. (2013) · The Lancet · doi:10.1016/s0140-6736(13)61914-5 · Cited by 586
Safety and Efficacy of a Monoclonal Antibody to Proprotein Convertase Subtilisin/Kexin Type 9 Serine Protease, SAR236553/REGN727, in Patients With Primary Hypercholesterolemia Receiving Ongoing Stable Atorvastatin Therapy
McKenney, J. M., Koren, M. J., Kereiakes, D. J., Hanotin, C., Ferrand, A.-C., & Stein, E. A. (2012) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2012.03.007 · Cited by 514
Self-citation
Understanding statin use in America and gaps in patient education (USAGE): an internet-based survey of 10,138 current and former statin users
Cohen, J. D., Brinton, E. A., Ito, M. K., & Jacobson, T. A. (2012) · Journal of Clinical Lipidology · doi:10.1016/j.jacl.2012.03.003 · Cited by 486
Efficacy and tolerability of adding prescription Omega-3 fatty acids 4 g/d to Simvastatin 40 mg/d in hypertriglyceridemic patients: An 8-week, randomized, double-blind, placebo-controlled study
Davidson, M. H., Stein, E. A., Bays, H. E., Maki, K. C., Doyle, R. T., Shalwitz, R. A., Ballantyne, C. M., & Ginsberg, H. N. (2007) · Clinical Therapeutics · doi:10.1016/j.clinthera.2007.07.018 · Cited by 385
Self-citation
Lipid levels in patients hospitalized with coronary artery disease: An analysis of 136,905 hospitalizations in Get With The Guidelines
Sachdeva, A., Cannon, C. P., DEEDWANIA, P. C., LaBresh, K. A., Smith, S. C., Dai, D., Hernandez, A. F., & Fonarow, G. C. (2008) · American Heart Journal · doi:10.1016/j.ahj.2008.08.010 · Cited by 331
Self-citation
Lipid Treatment Assessment Project 2
Waters, D. D., Brotons, C., Chiang, C.-W., Ferrières, J., Foody, J. M., Jukema, J. W., Santos, R. D., Verdejo, J., Messig, M., McPherson, R., et al. (2009) · Circulation · doi:10.1161/circulationaha.108.838466 · Cited by 305
Apolipoprotein B and Cardiovascular Disease: Biomarker and Potential Therapeutic Target
Behbodikhah, J., Ahmed, S., Elyasi, A., Kasselman, L. J., Leon, J. D., Glass, A. D., & Reiss, A. B. (2021) · Metabolites · doi:10.3390/metabo11100690 · Cited by 299
Clinical utility of inflammatory markers and advanced lipoprotein testing: Advice from an expert panel of lipid specialists
Davidson, M. H., Ballantyne, C. M., Jacobson, T. A., Bittner, V. A., Braun, L. T., Brown, A. S., Brown, W. V., Cromwell, W. C., Goldberg, R. B., McKenney, J. M., et al. (2011) · Journal of Clinical Lipidology · doi:10.1016/j.jacl.2011.07.005 · Cited by 262
Self-citation
Predictors of statin adherence, switching, and discontinuation in the USAGE survey: Understanding the use of statins in America and gaps in patient education
Wei, M. Y., Ito, M. K., Cohen, J. D., Brinton, E. A., & Jacobson, T. A. (2013) · Journal of clinical lipidology · doi:10.1016/j.jacl.2013.03.001 · Cited by 260
Alirocumab inhibits atherosclerosis, improves the plaque morphology, and enhances the effects of a statin
Kühnast, S., van der Hoorn, J. W. A., Pieterman, E. J., van den Hoek, A. M., Sasiela, W. J., Gusarova, V., Peyman, A., Schäfer, H.-L., Schwahn, U., Jukema, J. W., et al. (2014) · Journal of Lipid Research · doi:10.1194/jlr.m051326 · Cited by 204
CYP3A4*22: Promising Newly IdentifiedCYP3A4Variant Allele for Personalizing Pharmacotherapy
Elens, L., van Gelder, T., Hesselink, D. A., Haufroid, V., & van Schaik, R. H. (2012) · Pharmacogenomics · doi:10.2217/pgs.12.187 · Cited by 205
Efficacy and safety of rosuvastatin 40 mg alone or in combination with ezetimibe in patients at high risk of cardiovascular disease (results from the EXPLORER study)
Ballantyne, C. M., Weiss, R., Moccetti, T., Vogt, A., Eber, B., Sosef, F., & Duffield, E. (2007) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2006.10.022 · Cited by 196
Self-citation
The importance of non–HDL cholesterol reporting in lipid management
Blaha, M. J., Blumenthal, R. S., Brinton, E. A., & Jacobson, T. A. (2008) · Journal of clinical lipidology · doi:10.1016/j.jacl.2008.06.013 · Cited by 195
Comparing Impact and Cost-Effectiveness of Primary Prevention Strategies for Lipid-Lowering
Pletcher, M. J., Lazar, L., Bibbins-Domingo, K. B., Moran, A., Rodondi, N., Coxson, P. G., Lightwood, J., Williams, L., & Goldman, L. (2009) · Annals of Internal Medicine · doi:10.7326/0003-4819-150-4-200902170-00005 · Cited by 187
Selected physiologic compatibilities and incompatibilities between human and porcine organ systems
Ibrahim, Z., Busch, J., Awwad, M., Wagner, R. A., Wells, K. D., & Cooper, D. K. C. (2006) · Xenotransplantation · doi:10.1111/j.1399-3089.2006.00346.x · Cited by 184
Effect of Mipomersen, an Apolipoprotein B Synthesis Inhibitor, on Low-Density Lipoprotein Cholesterol in Patients With Familial Hypercholesterolemia
Akdim, F., Visser, M. E., Tribble, D. L., Baker, B. F., Stroes, E. S. G., Yu, R. Z., Flaim, J., Su, J. Q., Stein, E. A., & Kastelein, J. J. P. (2010) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2010.01.003 · Cited by 175
Assessment of omega-3 carboxylic acids in statin-treated patients with high levels of triglycerides and low levels of high-density lipoprotein cholesterol: rationale and design of the STRENGTH trial
Nicholls, S. J., Lincoff, A. M., Bash, D., Ballantyne, C. M., Barter, P. J., Davidson, M. H., Kastelein, J. J. P., Koenig, W., McGuire, D. K., Mozaffarian, D., et al. (2018) · Clinical Cardiology · doi:10.1002/clc.23055 · Cited by 167
Self-citation
Contemporary Management of Dyslipidemia in High-Risk Patients: Targets Still Not Met
Yan, A. T.-K., Yan, R. T., Tan, M., Hackam, D. G., Leblanc, K., Kertland, H. R., Tsang, J. L. Y., Jaffer, S., Kates, M. L., Leiter, L. A., et al. (2006) · The American Journal of Medicine · doi:10.1016/j.amjmed.2005.11.015 · Cited by 159
Prevention and Treatment
Diamond, G. A., & Kaul, S. (2008) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2007.07.083 · Cited by 149
Clinical efficacy and safety of statins in managing cardiovascular risk
Kapur, N. K. (2008) · Vascular Health and Risk Management · doi:10.2147/vhrm.s1653 · Cited by 143
Brothers in Arms: ABCA1- and ABCG1-Mediated Cholesterol Efflux as Promising Targets in Cardiovascular Disease Treatment
Frambach, S. J. C. M., de Haas, R., Smeitink, J. A. M., Rongen, G. A. P. J. M., Rüssel, F. G. M., & Schirris, T. J. J. (2019) · Pharmacological Reviews · doi:10.1124/pr.119.017897 · Cited by 146
Prevalence of Dyslipidemia and Lipid Goal Attainment in Statin‐Treated Subjects From 3 Data Sources: A Retrospective Analysis
Jones, P. H., Nair, R., & Thakker, K. M. (2012) · Journal of the American Heart Association · doi:10.1161/jaha.112.001800 · Cited by 119
Novel CYP3A4 intron 6 single nucleotide polymorphism is associated with simvastatin-mediated cholesterol reduction in The Rotterdam Study
Elens, L., Becker, M. L., Haufroid, V., Albert Hofman, D., Visser, L. E., Uitterlinden, A. G., Stricker, B. H. C., & van Schaik, R. H. N. (2011) · Pharmacogenetics and Genomics · doi:10.1097/fpc.0b013e32834c6edb · Cited by 114
Efficacy and tolerability of adding coenzyme A 400 U/d capsule to stable statin therapy for the treatment of patients with mixed dyslipidemia: an 8-week, multicenter, double-Blind, randomized, placebo-controlled study
Lai, J., Wu, B., Xuan, T., Liu, Z., & Chen, J.-Z. (2014) · Lipids in Health and Disease · doi:10.1186/1476-511x-13-1 · Cited by 112
Relative Atherogenicity and Predictive Value of Non–High-Density Lipoprotein Cholesterol for Coronary Heart Disease
Miller, M., Ginsberg, H. N., & Schaefer, E. J. (2008) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2007.11.046 · Cited by 102
Prevalencia y características de la dislipemia en pacientes en prevención primaria y secundaria tratados con estatinas en España. Estudio DYSIS-España
González‐Juanatey, J. R., Millán, J., Alegría, E., Guijarro, C., Lozano, J. V., & Vitale, G. C. (2011) · Revista Española de Cardiología · doi:10.1016/j.recesp.2010.10.030 · Cited by 99
Knowledge and attitudes of primary care physicians in the management of patients at risk for cardiovascular events
Doroodchi, H., Abdolrasulnia, M., Foster, J. A., Foster, E., Turakhia, M. P., Skelding, K. A., Sagar, K. B., & Casebeer, L. L. (2008) · BMC Family Practice · doi:10.1186/1471-2296-9-42 · Cited by 98
Managing the underestimated risk of statin-associated myopathy
Rallidis, L. S., Fountoulaki, K., & ANASTASIOU‐NANA, M. I. (2011) · International Journal of Cardiology · doi:10.1016/j.ijcard.2011.07.048 · Cited by 99
Observational Study on the Beneficial Effect of Preoperative Statins in Reducing Atrial Fibrillation After Coronary Surgery
Mariscalco, G., Lorusso, R., Klersy, C., Ferrarese, S., Tozzi, M., Vanoli, D., Domenico, B. V., & Sala, A. (2007) · The Annals of Thoracic Surgery · doi:10.1016/j.athoracsur.2007.05.021 · Cited by 97
Treatment With Ezetimibe Plus Low-Dose Atorvastatin Compared With Higher-Dose Atorvastatin Alone
Piorkowski, M., Fischer, S., Stellbaum, C., Jaster, M., Martus, P., Morguet, A. J., Schultheiss, H., & Rauch, U. (2007) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2006.10.064 · Cited by 93
Non-HDL cholesterol as a metric of good quality of care: opportunities and challenges.
Virani, S. S. (2011) · Europe PMC (PubMed Central) · Cited by 91
Effect of Bile Acid Sequestrants on the Risk of Cardiovascular Events: A Mendelian Randomization Analysis
Ross, S., D’Mello, M., Anand, S. S., Eikelboom, J., CARDIoGRAMplusC4D Consortium*, Stewart, A. F. R., Samani, N. J., Roberts, R., & Paré, G. (2015) · Circulation: Cardiovascular Genetics · doi:10.1161/circgenetics.114.000952 · Cited by 90
Efficacy and Safety of Ezetimibe Added on to Atorvastatin (40 mg) Compared With Uptitration of Atorvastatin (to 80 mg) in Hypercholesterolemic Patients at High Risk of Coronary Heart Disease
Leiter, L. A., Bays, H. E., Conard, S. E., Bird, S. R., Rubino, J., Hanson, M. E., Tomassini, J. E., & Tershakovec, A. M. (2008) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2008.09.076 · Cited by 90
Nine-year trends in achievement of risk factor goals in the US and European outpatients with cardiovascular disease
Steinberg, B. A., Bhatt, D. L., Mehta, S. R., Poole-Wilson, P. A., O’Hagan, P., Montalescot, G., Ballantyne, C. M., & Cannon, C. P. (2008) · American Heart Journal · doi:10.1016/j.ahj.2008.05.020 · Cited by 90
Self-citation
Plasma PCSK9 is increased by Fenofibrate and Atorvastatin in a non-additive fashion in diabetic patients
Costet, P., Hoffmann, M. M., Cariou, B., Guyomarch, B., Konrad, T., & Winkler, K. E. (2010) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2010.05.027 · Cited by 92
Pharmacogenetic Predictors of Statin-Mediated Low-Density Lipoprotein Cholesterol Reduction and Dose Response
Voora, D., Shah, S. H., Reed, C. R., Zhai, J., Crosslin, D. R., Messer, C. J., Salisbury, B. A., & Ginsburg, G. S. (2008) · Circulation Cardiovascular Genetics · doi:10.1161/circgenetics.108.795013 · Cited by 87
The 'forgotten' bile acid sequestrants: is now a good time to remember?
Bays, H. E., & Goldberg, R. B. (2007) · American Journal of Therapeutics · doi:10.1097/mjt.0b013e31815a69fc · Cited by 83
A Review of Currently Available Fenofibrate and Fenofibric Acid Formulations
Ling (2013) · Cardiology Research · doi:10.4021/cr270w · Cited by 85
Reducing Residual Risk for Patients on Statin Therapy: The Potential Role of Combination Therapy
Davidson, M. H. (2005) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2005.08.002 · Cited by 81
Self-citation
Clinical Relevance of Non-HDL Cholesterol in Patients With Diabetes
Peters, A. L. (2008) · Clinical Diabetes · doi:10.2337/diaclin.26.1.3 · Cited by 78
Implications of Cardiac Risk and Low-Density Lipoprotein Cholesterol Distributions in the United States for the Diagnosis and Treatment of Dyslipidemia
Keevil, J. G., Cullen, M. W., Gangnon, R. E., McBride, P. E., & Stein, J. H. (2007) · Circulation · doi:10.1161/circulationaha.106.645473 · Cited by 76
Statin/fibrate combination in patients with metabolic syndrome or diabetes: evaluating the risks of pharmacokinetic drug interactions
Davidson, M. H. (2005) · Expert Opinion on Drug Safety · doi:10.1517/14740338.5.1.145 · Cited by 76
Self-citation
Anacetrapib reduces progression of atherosclerosis, mainly by reducing non-HDL-cholesterol, improves lesion stability and adds to the beneficial effects of atorvastatin
Kühnast, S., van der Tuin, S. J. L., van der Hoorn, J. W. A., van Klinken, J. B., Simic, B., Pieterman, E. J., Havekes, L. M., Landmesser, U., Lüscher, T. F., van Dijk, K. W., et al. (2014) · European Heart Journal · doi:10.1093/eurheartj/ehu319 · Cited by 79
Effectiveness of Combined Statin Plus Omega-3 Fatty Acid Therapy for Mixed Dyslipidemia
Barter, P. J., & Ginsberg, H. N. (2008) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2008.05.056 · Cited by 73
Effects of prescription omega-3-acid ethyl esters on lipoprotein particle concentrations, apolipoproteins AI and CIII, and lipoprotein-associated phospholipase A2 mass in statin-treated subjects with hypertriglyceridemia
Davidson, M. H., Maki, K. C., Bays, H., Carter, R., & Ballantyne, C. M. (2009) · Journal of Clinical Lipidology · doi:10.1016/j.jacl.2009.08.001 · Cited by 71
Self-citation
Lipid-altering efficacy of ezetimibe/simvastatin 10/20 mg compared with rosuvastatin 10 mg in high-risk hypercholesterolaemic patients inadequately controlled with prior statin monotherapy - The IN-CROSS study
Farnier, M., Averna, M. R., Missault, L. H., Vaverková, H., Viigimaa, M., Massaad, R., Vandormael, K., Johnson‐Levonas, A. O., & Brudi, P. (2009) · International Journal of Clinical Practice · doi:10.1111/j.1742-1241.2009.02022.x · Cited by 71
Use of Lipid-Lowering Medications and the Likelihood of Achieving Optimal LDL-Cholesterol Goals in Coronary Artery Disease Patients
Karalis, D. G., Victor, B. M., Ahedor, L., & Liu, L. (2012) · Cholesterol · doi:10.1155/2012/861924 · Cited by 68
ACCF/AHA/ACP 2009 Competence and Training Statement: A Curriculum on Prevention of Cardiovascular Disease
Merz, C. N. B., Alberts, M. J., Balady, G. J., Ballantyne, C. M., Berra, K. A., Black, H. R., Blumenthal, R. S., Davidson, M. H., Fazio, S. B., Ferdinand, K. C., et al. (2009) · Circulation · doi:10.1161/circulationaha.109.192640 · Cited by 64
Self-citation
Applying the Evidence
Saposnik, G., Goodman, S. G., Leiter, L. A., Yan, R. T., FITCHETT, D. H., Bayer, N., Casanova, A., Langer, A., Yan, A. T.-K., & Guidelines-Oriented Approach to Lipid-Lowering (GOALL) Registries Investigators (2009) · Stroke · doi:10.1161/strokeaha.108.533018 · Cited by 64
Differences between clinical trial efficacy and real-world effectiveness.
Davidson, M. H. (2006) · PubMed · Cited by 57
Self-citation
Innovative pharmaceutical interventions in cardiovascular disease: Focusing on the contribution of non-HDL-C/LDL-C-lowering versus HDL-C-raisingA systematic review and meta-analysis of relevant preclinical studies and clinical trials
Kühnast, S., Fiocco, M. F., van der Hoorn, J. W. A., Princen, H. M. G., & Jukema, J. W. (2015) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2015.03.089 · Cited by 58
Frequency and correlates of treatment intensification for elevated cholesterol levels in patients with cardiovascular disease
Virani, S. S., Woodard, L., Chitwood, S. S., Landrum, C. R., Urech, T. H., Wang, D., Murawsky, J., Ballantyne, C. M., & Petersen, L. A. (2011) · American Heart Journal · doi:10.1016/j.ahj.2011.07.013 · Cited by 56
Self-citation
Long-Term Safety and Efficacy of a Combination of Niacin Extended Release and Simvastatin in Patients with Dyslipidemia
Karas, R. H., Kashyap, M. L., Knopp, R. H., Keller, L. H., Bajorunas, D. R., & Davidson, M. H. (2008) · American Journal of Cardiovascular Drugs · doi:10.2165/00129784-200808020-00001 · Cited by 56
Self-citation
Effects of Prescription Omega-3-Acid Ethyl Esters on Non—High-Density Lipoprotein Cholesterol When Coadministered With Escalating Doses of Atorvastatin
Bays, H. E., McKenney, J., Maki, K. C., Doyle, R. T., Carter, R. N., & Stein, E. (2010) · Mayo Clinic Proceedings · doi:10.4065/mcp.2009.0397 · Cited by 54
Self-citation
Prevalence of dyslipidemia in statin-treated patients in Canada: Results of the DYSlipidemia International Study (DYSIS)
Goodman, S. G., Langer, A., Bastien, N. R., McPherson, R., Francis, G. A., Genest, J. J., & Leiter, L. A. (2010) · Canadian Journal of Cardiology · doi:10.1016/s0828-282x(10)70454-2 · Cited by 54
PCSK9 inhibition in LDL cholesterol reduction: Genetics and therapeutic implications of very low plasma lipoprotein levels
Marais, A. D., Kim, J. B., Wasserman, S. M., & Lambert, G. C. (2014) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2014.07.004 · Cited by 55
Molecular pathways and agents for lowering LDL-cholesterol in addition to statins
Costet, P. (2010) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2010.02.006 · Cited by 55
ACCF/AHA/ACP 2009 Competence and Training Statement: A Curriculum on Prevention of Cardiovascular Disease
Merz, C. N. B., Alberts, M. J., Balady, G. J., Ballantyne, C. M., Berra, K. A., Black, H. R., Blumenthal, R. S., Davidson, M. H., Fazio, S. B., Ferdinand, K. C., et al. (2009) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2009.05.019 · Cited by 53
Self-citation
Critical appraisal of the role of pitavastatin in treating dyslipidemias and achieving lipid goals
Saitō, Y. (2009) · Vascular Health and Risk Management · doi:10.2147/vhrm.s5551 · Cited by 53
A Review of Lipid Management in Primary and Secondary Prevention
Dembowski, E., & Davidson, M. H. (2009) · Journal of Cardiopulmonary Rehabilitation and Prevention · doi:10.1097/hcr.0b013e318192754e · Cited by 53
Self-citation
Clinical features of familial Mediterranean fever: an Italian overview.
Manna, R., Cerquaglia, C., Curigliano, V., Fonnesu, C., Giovinale, M., Verrecchia, E., Montalto, M., Socio, G. D., Soriano, A., Regina, M. L., et al. (2009) · PubMed · Cited by 51
Effects of fenofibrate on atherogenic dyslipidemia in hypertriglyceridemic subjects
Davidson, M. H., Bays, H. E., Stein, E., Maki, K. C., Shalwitz, R. A., & Doyle, R. (2006) · Clinical Cardiology · doi:10.1002/clc.4960290609 · Cited by 51
Self-citation
Conocimiento y aplicación de las guías de práctica clínica sobre riesgo cardiovascular en las consultas generales y especializadas
González‐Juanatey, J. R., Alegría-Ezquerra, E., Aznar, J., Bertoméu, V., Franch‐Nadal, J., & Palma-Gámiz, J. L. (2006) · Revista Española de Cardiología · doi:10.1157/13091884 · Cited by 51
Atherosclerosis: Immune and Inflammatory Aspects
Reiss, A. B., & Glass, A. D. (2006) · Journal of Investigative Medicine · doi:10.2310/6650.2006.05051 · Cited by 50
Ezetimibe Ameliorates Metabolic Disorders and Microalbuminuria in Patients with Hypercholesterolemia
Yagi, S., Akaike, M., Aihara, K., Iwase, T., Ishikawa, K., Yoshida, S., Sumitomo-Ueda, Y., Kusunose, K., Niki, T., Yamaguchi, K., et al. (2010) · Journal of Atherosclerosis and Thrombosis · doi:10.5551/jat.2378 · Cited by 47
Institutional, provider, and patient correlates of low-density lipoprotein and non–high-density lipoprotein cholesterol goal attainment according to the Adult Treatment Panel III guidelines
Virani, S. S., Woodard, L., Landrum, C. R., Pietz, K., Wang, D., Ballantyne, C. M., & Petersen, L. A. (2011) · American Heart Journal · doi:10.1016/j.ahj.2011.03.023 · Cited by 46
Self-citation
Prospective Analysis of LDL-C Goal Achievement and Self-Reported Medication Adherence Among Statin Users in Primary Care
Bermingham, M., Hayden, J. C., Dawkins, I. R., Miwa, S., Gibson, D., McDonald, K., & Ledwidge, M. T. (2011) · Clinical Therapeutics · doi:10.1016/j.clinthera.2011.07.007 · Cited by 46
Mipomersen is a promising therapy in the management of hypercholesterolemia: a meta-analysis of randomized controlled trials
Li, N., Li, Q., Tian, X.-Q., Qian, H.-Y., & Yang, Y.-J. (2014) · American Journal of Cardiovascular Drugs · doi:10.1007/s40256-014-0077-0 · Cited by 45
Apolipoprotein B synthesis inhibition: results from clinical trials
Visser, M. E., Kastelein, J. J. P., & Stroes, E. S. G. (2010) · Current Opinion in Lipidology · doi:10.1097/mol.0b013e32833af4c1 · Cited by 41
Combination therapy with ezetimibe and simvastatin to achieve aggressive LDL reduction
Robinson, J. G., & Davidson, M. H. (2006) · Expert Review of Cardiovascular Therapy · doi:10.1586/14779072.4.4.461 · Cited by 44
Self-citation
Achieving Optimal Lipid Goals in Patients With Coronary Artery Disease
Karalis, D. G., Subramanya, R. D., Hessen, S. E., Liu, L., & Victor, M. F. (2011) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2010.11.006 · Cited by 44
Squalene synthase inhibition: A novel target for the management of dyslipidemia
Davidson, M. H. (2007) · Current Atherosclerosis Reports · doi:10.1007/bf02693932 · Cited by 43
Self-citation
Opening a New Lipid “Apo-thecary”: Incorporating Apolipoproteins as Potential Risk Factors and Treatment Targets to Reduce Cardiovascular Risk
Jacobson, T. A. (2011) · Mayo Clinic Proceedings · doi:10.4065/mcp.2011.0128 · Cited by 43
Lipid-lowering therapy: who can benefit
Lewis, S. J. (2011) · Vascular Health and Risk Management · doi:10.2147/vhrm.s23113 · Cited by 44
LDL-C goal Attainment Among Patients Newly Diagnosed With Coronary Heart Disease or Diabetes in a Commercial HMO
Nag, S. S., Daniel, G. W., Bullano, M. F., Kamal‐Bahl, S. J., Sajjan, S. G., Hu, H. X., & Alexander, C. M. (2007) · Journal of Managed Care Pharmacy · doi:10.18553/jmcp.2007.13.8.652 · Cited by 41
Reduced treatment success in lipid management among women with coronary heart disease or risk equivalents: Results of a national survey
Ansell, B. J., Fonarow, G. C., Maki, K. C., Dicklin, M. R., Bell, M., & Davidson, M. H. (2006) · American Heart Journal · doi:10.1016/j.ahj.2006.05.013 · Cited by 41
Self-citation
Unmet need in the hyperlipidaemia population with high risk of cardiovascular disease: a targeted literature review of observational studies
Mitchell, S., Roso, S., Samuel, M., & Pladevall-Vila, M. (2016) · BMC Cardiovascular Disorders · doi:10.1186/s12872-016-0241-3 · Cited by 40
Perspectives on low-density-lipoprotein cholesterol goal achievement
Catapano, A. L. (2009) · Current Medical Research and Opinion · doi:10.1185/03007990802631438 · Cited by 40
Treating mixed hyperlipidemia and the atherogenic lipid phenotype for prevention of cardiovascular events
Rubenfire, M., Brook, R. D., & Rosenson, R. S. (2010) · The American Journal of Medicine · doi:10.1016/j.amjmed.2010.03.024 · Cited by 40
Prevalence and overlap of different lipid abnormalities in statin-treated patients at high cardiovascular risk in clinical practice in Germany
Gitt, A. K., Jünger, C., Smolka, W., & Bestehorn, K. P. (2010) · Clinical Research in Cardiology · doi:10.1007/s00392-010-0177-z · Cited by 40
Achieving Low-Density Lipoprotein Cholesterol Goals in High-Risk Patients in Managed Care: Comparison of Rosuvastatin, Atorvastatin, and Simvastatin in the SOLAR Trial
Insull, W., Ghali, J. K., Hassman, D. R., Yčas, J. W., Gandhi, S. K., & Miller, E. (2007) · Mayo Clinic Proceedings · doi:10.4065/82.5.543 · Cited by 40
A comparison of non-HDL and LDL cholesterol goal attainment in a large, multinational patient population: The Lipid Treatment Assessment Project 2
Santos, R. D., Waters, D. D., Tarasenko, L., Messig, M., Jukema, J. W., Chiang, C.-W., Ferrieres, J., & Foody, J. M. (2012) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2012.06.052 · Cited by 39
Lipid-lowering intensification and low-density lipoprotein cholesterol achievement from hospital admission to 1-year follow-up after an acute coronary syndrome event: Results from the Medications ApplIed aNd SusTAINed Over Time (MAINTAIN) registry
Melloni, C., Shah, B. R., Ou, F., Roe, M. T., Smith, S. C., Pollack, C. V., Ohman, M. E., Gibler, W. B., Peterson, E. D., & Alexander, K. P. (2010) · American Heart Journal · doi:10.1016/j.ahj.2010.09.008 · Cited by 39
Relation Between Obesity and the Attainment of Optimal Blood Pressure and Lipid Targets in High Vascular Risk Outpatients
Bhan, V., Yan, R. T., Leiter, L. A., FITCHETT, D. H., Langer, A., Lonn, E., Tan, M., Silagy, S., Goodman, S. G., & Yan, A. T.-K. (2010) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2010.06.055 · Cited by 38
Circulating PCSK9 levels and CETP plasma activity are independently associated in patients with metabolic diseases
Girona, J., Ibarretxe, D., Plana, N., Guaita‐Esteruelas, S., Amigó, N., Heras, M., & Masana, L. (2016) · Cardiovascular Diabetology · doi:10.1186/s12933-016-0428-z · Cited by 38
Comparison of the efficacy and safety of a combination tablet of niacin extended-release and simvastatin with simvastatin 80 mg monotherapy: the SEACOAST II (high-dose) study
Ballantyne, C. M., Davidson, M. H., McKenney, J. M., Keller, L. H., Bajorunas, D. R., & Karas, R. H. (2008) · Journal of clinical lipidology · doi:10.1016/j.jacl.2008.02.004 · Cited by 38
Self-citation
Novel nonstatin strategies to lower low-density lipoprotein cholesterol
Davidson, M. H. (2008) · Current Atherosclerosis Reports · doi:10.1007/s11883-009-0011-0 · Cited by 37
Self-citation
Ethnic differences in achievement of cholesterol treatment goals
Clark, L. T., Maki, K. C., Galant, R., Maron, D. J., Pearson, T. A., & Davidson, M. H. (2006) · Journal of General Internal Medicine · doi:10.1111/j.1525-1497.2006.00349.x · Cited by 38
Self-citation
Fish oil in the treatment of dyslipidemia
Goldberg, R. B., & Sabharwal, A. K. (2008) · Current Opinion in Endocrinology Diabetes and Obesity · doi:10.1097/med.0b013e3282f76728 · Cited by 37
Prevalence and Characteristics of Lipid Abnormalities in Patients Treated With Statins in Primary and Secondary Prevention in Spain. DYSIS-Spain Study
González‐Juanatey, J. R., Millán, J., Alegría, E., Guijarro, C., Lozano, J. V., & Vitale, G. C. (2011) · Revista Española de Cardiología (English Edition) · doi:10.1016/j.rec.2010.10.030 · Cited by 35
Ezetimibe added to atorvastatin compared with doubling the atorvastatin dose in patients at high risk for coronary heart disease with diabetes mellitus, metabolic syndrome or neither
Conard, S. E., Bays, H. E., Leiter, L. A., Bird, S., Lin, J., Hanson, M. E., Shah, A. K., & Tershakovec, A. M. (2009) · Diabetes Obesity and Metabolism · doi:10.1111/j.1463-1326.2009.01152.x · Cited by 35
A novel small molecule liver X receptor transcriptional regulator, nagilactone B, suppresses atherosclerosis in apoE-deficient mice
Gui, Y., Yao, S., Yan, H., Hu, L., Yu, C., Gao, F., Xi, C., Li, H., Ye, Y., & Wang, Y. (2016) · Cardiovascular Research · doi:10.1093/cvr/cvw183 · Cited by 35
Ezetimibe Monotherapy Ameliorates Vascular Function in Patients with Hypercholesterolemia Through Decreasing Oxidative Stress
Kurobe, H., Aihara, K., Higashida, M., Hirata, Y., Nishiya, M., Matsuoka, Y., Kanbara, T., Nakayama, T., Kinoshita, H., Sugano, M., et al. (2011) · Journal of Atherosclerosis and Thrombosis · doi:10.5551/jat.9548 · Cited by 35
Other Therapies for Reducing Low-Density Lipoprotein Cholesterol: Medications in Development
Stein, E. A. (2009) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/j.ecl.2008.11.011 · Cited by 34
Attainment of low-density lipoprotein cholesterol goals in coronary artery disease
Kauffman, A. B., Olson, K. L., Youngblood, M., Zadvorny, E. B., Delate, T., & Merenich, J. A. (2010) · Journal of clinical lipidology · doi:10.1016/j.jacl.2010.03.002 · Cited by 33

Authors: Davidson, M. H., Maki, K. C., Pearson, T. A., Pasternak, R. C., Deedwania, P. C., McKenney, J. M., Fonarow, G. C., Maron, D. J., Ansell, B. J., Clark, L. T., & Ballantyne, C. M.
Affiliations: University of Rochester Medicine (US)
Massachusetts General Hospital (US)
National Clinical Research (US)
University of California, Los Angeles (US)
Vanderbilt University (US)
SUNY Downstate Health Sciences University (US)
Baylor College of Medicine (US)
Corresponding author: Davidson, Michael H.
ORCID: Davidson, Michael H.
Maki, Kevin C.
Deedwania, Prakash C.
Fonarow, Gregg C.
Maron, David J.
Clark, Luther T.
Ballantyne, Christie M.
Venue: The American Journal of Cardiology
Publisher: Elsevier BV
Published: 2005-08
Volume: 96
Issue: 4
Pages: 556-563
ISSN: 0002-9149 (ISSN-L)
DOI: 10.1016/j.amjcard.2005.04.019
OpenAlex: W1969054950
Cited by: 270
References: 6
Citations by year: 2026: 1 · 2024: 1 · 2022: 2 · 2021: 1 · 2020: 3 · 2019: 5 · 2018: 3 · 2017: 5 · 2016: 4 · 2015: 12 · 2014: 15 · 2013: 16 · 2012: 19
FWCI: 28.64
Type: journal article
Language: en
Open access: closed
Licence: www.elsevier.com/tdm/userlicense/1.0/ (tdm)
Locations: The American Journal of Cardiology (publishedVersion)
PubMed (publishedVersion)
Topics: Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Health Promotion and Cardiovascular Prevention
Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
Keywords: National Cholesterol Education Program, Adult Treatment Panel III, non-HDL cholesterol, cardiovascular risk stratification, very high-risk patients, coronary artery disease, diabetes mellitus, treatment gap, lipid control, aggressive lipid-lowering therapy
MeSH terms: Anticholesteremic Agents, Cholesterol, Coronary Artery Disease, Female, Follow-Up Studies, Health Surveys, Humans, Male, Middle Aged, Retrospective Studies, Risk Factors, Medical Laboratory Science, Hypertriglyceridemia, Program Evaluation, Treatment Outcome, Practice Guidelines as Topic

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Results of the National Cholesterol Education (NCEP) Program Evaluation Project Utilizing Novel E-Technology (NEPTUNE) II Survey and Implications for Treatment Under the Recent NCEP Writing Group Recommendations

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks